Suraksha Diagnostic has received the Securities and Exchange Board of India’s (SEBI's) approval to float an initial public offering (IPO). The company’s proposed IPO consists of an Offer-for-Sale (OFS) of up to 1.92 crore equity shares by promoters and investor shareholders, with no fresh issue component.
The company, which filed the draft red herring prospectus with the SEBI in July 2024, got the regulator’s approval on September 30, 2024. ICICI Securities, Nuvama Wealth Management and SBI Capital Markets are the book-running lead managers to the issue. The equity shares are proposed to be listed on BSE and NSE.
Suraksha Diagnostic offers a one-stop integrated solution for pathology and radiology testing and medical consultation services to its customers through its extensive operational network, consisting of a flagship central reference laboratory, 8 satellite laboratories and 194 customer touchpoints which include 48 diagnostic centres, and 146 sample collection centres (primarily franchised), across West Bengal, Bihar, Assam and Meghalaya as of March 31, 2024.
Company Name | CMP |
---|---|
Apollo Hospital Ent. | 7248.75 |
Max Healthcare Inst | 1166.60 |
Narayana Hrudayalay | 1286.30 |
Aster DM Healthcare | 486.85 |
Global Health | 1098.95 |
View more.. |